These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 19455459)

  • 1. [18F]-fluorodeoxyglucose positron emission tomography combined with computed tomography detection of asymptomatic late pulmonary toxicity in patients with non-Hodgkin lymphoma treated with rituximab-containing chemotherapy.
    Kalkanis D; Stefanovic A; Paes F; Escalon MP; Serafini A; Lossos IS
    Leuk Lymphoma; 2009 Jun; 50(6):904-11. PubMed ID: 19455459
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Incidental findings on follow-up fluorodeoxyglucose positron emission tomography studies in lymphoma patients: beware the outlier.
    Aide N; Irving L; Hicks RJ
    Leuk Lymphoma; 2009 Jun; 50(6):865-7. PubMed ID: 19504393
    [No Abstract]   [Full Text] [Related]  

  • 3. 18F-FDG-PET/CT Pulmonary Infiltrates in Non-Hodgkin Lymphoma Patients Treated with Combined Immunochemotherapy: Incidence and Clinical Characteristics.
    Cohen YC; Berger T; Eshel L; Stern D; Bairey O; Raanani P; Shpilberg O
    Isr Med Assoc J; 2017 Jun; 19(6):372-377. PubMed ID: 28647936
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Predictive value of (18)F-FDG hybrid PET/CT for the clinical outcome in patients with non-Hodgkin's lymphoma prior to and after autologous stem cell transplantation.
    Qiao W; Zhao J; Wang C; Wang T; Xing Y
    Hematology; 2010 Feb; 15(1):21-7. PubMed ID: 20132658
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A case of nodular sclerosis Hodgkin's lymphoma repeatedly relapsing in the context of composite plasma cell-hyaline vascular Castleman's disease: successful response to rituximab and radiotherapy.
    Falchi L; Capello D; Palumbo B; Rauco A; Emili R; Cianciulli M; Pace R; Capparella V; Liberati F; Liberati AM
    Eur J Haematol; 2007 Nov; 79(5):455-61. PubMed ID: 17908180
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combined modality treatment for PET-positive non-Hodgkin lymphoma: favorable outcomes of combined modality treatment for patients with non-Hodgkin lymphoma and positive interim or postchemotherapy FDG-PET.
    Halasz LM; Jacene HA; Catalano PJ; Van den Abbeele AD; Lacasce A; Mauch PM; Ng AK
    Int J Radiat Oncol Biol Phys; 2012 Aug; 83(5):e647-54. PubMed ID: 22607911
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rituximab-induced pneumonitis on F-18 FDG PET/CT in patient with non-Hodgkin lymphoma.
    Song BI; Lee SW; Lee HJ; Kang S; Jeong SY; Seo JH; Ahn BC; Lee J; Shin KM
    Clin Nucl Med; 2010 Aug; 35(8):601-3. PubMed ID: 20631510
    [No Abstract]   [Full Text] [Related]  

  • 8. Interstitial pneumonitis during rituximab-containing chemotherapy for non-Hodgkin lymphoma.
    Liu X; Hong XN; Gu YJ; Wang BY; Luo ZG; Cao J
    Leuk Lymphoma; 2008 Sep; 49(9):1778-83. PubMed ID: 18798110
    [TBL] [Abstract][Full Text] [Related]  

  • 9. False-Positive 18F-FDG PET/CT Imaging: Dramatic "Flare Response" After Rituximab Administration.
    Skoura E; Ardeshna K; Halsey R; Wan S; Kayani I
    Clin Nucl Med; 2016 Mar; 41(3):e171-2. PubMed ID: 26647000
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase II study of first-line (131)I-rituximab radioimmunotherapy in follicular non-Hodgkin lymphoma and prognostic (18)F-fluorodeoxyglucose positron emission tomography.
    McQuillan AD; Macdonald WB; Turner JH
    Leuk Lymphoma; 2015 May; 56(5):1271-7. PubMed ID: 25065701
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pulmonary drug toxicity: FDG-PET findings in patients with lymphoma.
    Kazama T; Faria SC; Uchida Y; Ito H; Macapinlac HA
    Ann Nucl Med; 2008 Feb; 22(2):111-4. PubMed ID: 18311535
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fluorodeoxyglucose positron emission tomography (FDG-PET) and PET/computed tomography imaging characteristics of thyroid lymphoma and their potential clinical utility.
    Basu S; Li G; Bural G; Alavi A
    Acta Radiol; 2009 Mar; 50(2):201-4. PubMed ID: 19089692
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hodgkin disease: diagnostic value of FDG PET/CT after first-line therapy--is biopsy of FDG-avid lesions still needed?
    Schaefer NG; Taverna C; Strobel K; Wastl C; Kurrer M; Hany TF
    Radiology; 2007 Jul; 244(1):257-62. PubMed ID: 17581905
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Midtreatment 18F-fluorodeoxyglucose positron-emission tomography in aggressive non-Hodgkin lymphoma.
    Zinzani PL; Gandolfi L; Broccoli A; Argnani L; Fanti S; Pellegrini C; Stefoni V; Derenzini E; Quirini F; Baccarani M
    Cancer; 2011 Mar; 117(5):1010-8. PubMed ID: 20960498
    [TBL] [Abstract][Full Text] [Related]  

  • 15. 18F-Fluorodeoxyglucose Positron Emission Tomography/Magnetic Resonance in Lymphoma: Comparison With 18F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography and With the Addition of Magnetic Resonance Diffusion-Weighted Imaging.
    Giraudo C; Raderer M; Karanikas G; Weber M; Kiesewetter B; Dolak W; Simonitsch-Klupp I; Mayerhoefer ME
    Invest Radiol; 2016 Mar; 51(3):163-9. PubMed ID: 26784400
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A possible role of 18F-FDG positron-emission tomography scanning in the early detection of rituximab-induced pneumonitis in patients with non-Hodgkin's lymphoma.
    Nieuwenhuizen L; Verzijlbergen FJ; Wiltink E; Grutters JC; Biesma DH
    Haematologica; 2008 Aug; 93(8):1267-9. PubMed ID: 18556403
    [No Abstract]   [Full Text] [Related]  

  • 17. Safety and activity of the anti-CD79B antibody-drug conjugate polatuzumab vedotin in relapsed or refractory B-cell non-Hodgkin lymphoma and chronic lymphocytic leukaemia: a phase 1 study.
    Palanca-Wessels MC; Czuczman M; Salles G; Assouline S; Sehn LH; Flinn I; Patel MR; Sangha R; Hagenbeek A; Advani R; Tilly H; Casasnovas O; Press OW; Yalamanchili S; Kahn R; Dere RC; Lu D; Jones S; Jones C; Chu YW; Morschhauser F
    Lancet Oncol; 2015 Jun; 16(6):704-15. PubMed ID: 25925619
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic significance of metabolic tumor burden by positron emission tomography/computed tomography in patients with relapsed/refractory diffuse large B-cell lymphoma.
    Tateishi U; Tatsumi M; Terauchi T; Ando K; Niitsu N; Kim WS; Suh C; Ogura M; Tobinai K
    Cancer Sci; 2015 Feb; 106(2):186-93. PubMed ID: 25495273
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Outcomes after involved-field radiation therapy (IFRT) with or without rituximab in patients with early-stage low-grade non-Hodgkin lymphoma (NHL) staged with CT and PET.
    Lukens JN; Nasta SD; Fram B; Glatstein E; Plastaras JP
    Am J Clin Oncol; 2014 Feb; 37(1):35-40. PubMed ID: 22992623
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pulmonary mucosa-associated lymphoid tissue lymphoma: computed tomography and ¹⁸F fluorodeoxyglucose-positron emission tomography/computed tomography imaging findings and follow-up.
    Zhang WD; Guan YB; Li CX; Huang XB; Zhang FJ
    J Comput Assist Tomogr; 2011; 35(5):608-13. PubMed ID: 21926857
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.